AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18678766 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (n=65)
Number of subjects: 142
Study 17538940 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 1000
Study 15898439 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange of cerebrospinal fluid and small dose of urokinase injection
Number of subjects: 134
Study 15898439 — intervention group
Group type: COMPARATOR
Intervention: Exchange of cerebrospinal fluid
Number of subjects: 134
Study 12472706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac suppositories (approximately 1 mg x kg(‐1))
Number of subjects: 40
Study 12472706 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study 9824788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral ganciclovir (6,000 mg/day)
Number of subjects: 0
Study 9824788 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir 2,000 mg every 8 hours alone
Number of subjects: 0
Study 9824788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir 2,000 mg every 8 hours in combination with didanosine 200 mg every 12 hours
Number of subjects: 0
Study 7982639 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 hepatitis C virus
Number of subjects: 98
Study 7982639 — intervention group
Group type: COMPARATOR
Intervention: Other genotypes
Number of subjects: 98
Study 7982639 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 hepatitis C virus
Number of subjects: 98
Study 2732807 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR‐alpha‐tocopherol 600 mg (900 IU) daily for 12 weeks
Number of subjects: 19
Study 2732807 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 19
Study 31955410 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth measures of heart rate (HR)
Number of subjects: 18
Study 31955410 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth measures of blood pressure (BP)
Number of subjects: 18
Study 31955410 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol
Number of subjects: 18
Study 31955410 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 18
Study 31955410 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 18
Study 31662385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid cardiac rehabilitation programme (10 supervised exercise sessions and individualised lifestyle counselling, transitioning to unsupervised delivery via text messages and phone calls after 4-6 weeks)
Number of subjects: 308
Study 31662385 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation programme (18-22 supervised exercise sessions and group education sessions about lifestyle)
Number of subjects: 308
Study 31662385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid cardiac rehabilitation programme
Number of subjects: 308
Study 28383338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (8 sessions over 8 weeks)
Number of subjects: 100
Study 28383338 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 25652127 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 600
Study 25652127 — intervention group
Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 600
Study 25652127 — intervention group
Group type: COMPARATOR
Intervention: Monthly sulphadoxine-pyrimethamine (SP)
Number of subjects: 600
Study 25652127 — intervention group
Group type: COMPARATOR
Intervention: Daily trimethoprim-sulphamethoxazole (TS)
Number of subjects: 600
Study 23623865 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (two enteric-coated tablets consisting of no less than 4.5 log10 TCID50 of live ADV-4 or ADV-7)
Number of subjects: 4040
Study 23623865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4040
Study 23623865 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 4040
Study 21521008 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblator (group A)
Number of subjects: 79
Study 21521008 — intervention group
Group type: COMPARATOR
Intervention: Laser tonsillotomy (group B)
Number of subjects: 79
Study 21521008 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (group C)
Number of subjects: 79
Study 19794312 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 1700-kcal diet (21% proteins, 27% lipids, 52% carbohydrates), cognitive-behavioural therapy (CBT), sertraline (50-150 mg/day), topiramate (25-150 mg/day)
Number of subjects: 30
Study 19794312 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 1700-kcal diet (21% proteins, 27% lipids, 52% carbohydrates), cognitive-behavioural therapy (CBT), sertraline (50-150 mg/day)
Number of subjects: 30
Study 19794312 — intervention group
Group type: COMPARATOR
Intervention: Group 3: Nutritional counselling and CBT
Number of subjects: 30
Study 16954722 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (300/100 mg once daily)
Number of subjects: 26
Study 16954722 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 26
Study 16954722 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 26
Study 16954722 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 26
Study 15350578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound only
Number of subjects: 593
Study 15350578 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound and abdominal computed tomography
Number of subjects: 593
Study 15350578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 593
Study 15286319 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stent placement
Number of subjects: 279
Study 15286319 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty followed by selective stent placement
Number of subjects: 279
Study 10765860 — intervention group
Group type: EXPERIMENTAL
Intervention: Celay inlays
Number of subjects: 17
Study 10765860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec inlays
Number of subjects: 17
Study 10765860 — intervention group
Group type: COMPARATOR
Intervention: Both Celay and Cerec inlays
Number of subjects: 17
Study 7781455 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain group
Number of subjects: 0
Study 7781455 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 7781455 — intervention group
Group type: COMPARATOR
Intervention: Dysphagia group
Number of subjects: 0
Study 7781455 — intervention group
Group type: COMPARATOR
Intervention: Controls and Dysphagia group
Number of subjects: 0
Study 2079570 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2a at a dose of 4.5 million units thrice weekly for 4 months
Number of subjects: 82
Study 2079570 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 82
Study 2079570 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2a
Number of subjects: 82
Study 492626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 22
Study 492626 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene (64 mg)
Number of subjects: 22
Study 492626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31815370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU/day
Number of subjects: 196
Study 31815370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/day
Number of subjects: 196
Study 31815370 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (control)
Number of subjects: 196
Study 31488190 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg
Number of subjects: 22
Study 31488190 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg
Number of subjects: 22
Study 31488190 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 22
Study 31488190 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg (consumers)
Number of subjects: 22
Study 31488190 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg (non-consumers)
Number of subjects: 22
Study 28291185 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical-site injection containing ropivacaine, epinephrine, and morphine
Number of subjects: 102
Study 28291185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 102
Study 28291185 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical-site injection
Number of subjects: 102
Study 26014344 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow oscillatory transcranial direct current stimulation (0.75 Hz) during stage 2 of non-rapid eye movement sleep
Number of subjects: 6
Study 26014344 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study 24740134 — intervention group
Group type: EXPERIMENTAL
Intervention: AB103 high-dose (0.5 mg/kg)
Number of subjects: 43
Study 24740134 — intervention group
Group type: EXPERIMENTAL
Intervention: AB103 low-dose (0.25 mg/kg)
Number of subjects: 43
Study 24740134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 24740134 — intervention group
Group type: EXPERIMENTAL
Intervention: AB103 high-dose
Number of subjects: 43
Study 24740134 — intervention group
Group type: EXPERIMENTAL
Intervention: AB103 low-dose
Number of subjects: 43
Study 24740134 — intervention group
Group type: EXPERIMENTAL
Intervention: AB103 (both doses)
Number of subjects: 43
Study 22995588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 616
Study 22995588 — intervention group
Group type: COMPARATOR
Intervention: Two-Dimensional Conventional Radiation Therapy (2D‐CRT)
Number of subjects: 616
Study 19083247 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-min standardized task of correcting a text on a word-processor with monetary reward for productivity
Number of subjects: 28
Study 19083247 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-min standardized task of correcting a text on a word-processor
Number of subjects: 28
Study 18085144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear point taping and pressing therapy
Number of subjects: 114
Study 18085144 — intervention group
Group type: COMPARATOR
Intervention: Western medication (Indomeixin enteric tablets)
Number of subjects: 114
Study 15129731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 g daily)
Number of subjects: 83
Study 15129731 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (4 g daily)
Number of subjects: 83
Study 12358303 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 5
Study 12358303 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 5
Study 12358303 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol
Number of subjects: 5
Study 9697664 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (0.04 microg/kg, increased by 0.04 microg/kg every 2 weeks to a maximum of 0.24 microg/kg)
Number of subjects: 78
Study 9697664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 7924122 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine coadministered with valproic acid
Number of subjects: 6
Study 2681509 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg daily
Number of subjects: 293
Study 2681509 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1000 mg daily
Number of subjects: 293
Study 2681509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 31216027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose PNE (N=20)
Number of subjects: 77
Study 31216027 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentrated dose PNE (N=20)
Number of subjects: 77
Study 31216027 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted low-dose PNE (N=20)
Number of subjects: 77
Study 31216027 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (N=17)
Number of subjects: 77
Study 30641350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.1, 0.2, 0.5, and 1.0 mg/kg)
Number of subjects: 99
Study 30641350 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (intravenous midazolam)
Number of subjects: 99
Study 30641350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 99
Study 28380474 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple uterine tourniquet
Number of subjects: 48
Study 28380474 — intervention group
Group type: COMPARATOR
Intervention: Single uterine tourniquet
Number of subjects: 48
Study 26561332 — intervention group
Group type: EXPERIMENTAL
Intervention: RAISE protocol (Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease)
Number of subjects: 108
Study 26561332 — intervention group
Group type: COMPARATOR
Intervention: Conventional Intravenous immunoglobulin (IVIG) protocol
Number of subjects: 108
Study 26561332 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive group (patients with positive anti-YPT and/or anti-YPM antibodies)
Number of subjects: 108
Study 26561332 — intervention group
Group type: COMPARATOR
Intervention: Negative group (patients without positive anti-YPT and/or anti-YPM antibodies)
Number of subjects: 108
Study 24745199 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-day accommodation protocol
Number of subjects: 12
Study 24745199 — intervention group
Group type: COMPARATOR
Intervention: No accommodation protocol (control)
Number of subjects: 12
Study 22333128 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle Tei index in HAHD patients
Number of subjects: 34
Study 22333128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial systolic pressure in HAHD patients
Number of subjects: 34
Study 22333128 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NT-proBNP level in HAHD patients
Number of subjects: 34
Study 22333128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial systolic pressure in mild pulmonary hypertension HAHD patients
Number of subjects: 34
Study 22333128 — intervention group
Group type: EXPERIMENTAL
Intervention: Tei index in mild pulmonary hypertension HAHD patients
Number of subjects: 34
Study 19835116 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongwan (CV 12) and Si-guan points combined with reinforcing-reducing manipulation of respiration
Number of subjects: 120
Study 19835116 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Fluoxetine Hydrochloride at 20 mg daily
Number of subjects: 120
Study 17767724 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year moderate-to-vigorous intensity aerobic and strength training exercise programme
Number of subjects: 189
Study 17767724 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining habitual exercise pattern
Number of subjects: 189
Study 15063441 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (intravenous)
Number of subjects: 13
Study 15063441 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13
Study 11811349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention based on Orem's self-care theory
Number of subjects: 134
Study 11811349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 134
Study 10215436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 211
Study 7804020 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse (disease concept)
Number of subjects: 0
Study 7804020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abuse (sin conception)
Number of subjects: 0
Study 7804020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (habit conception)
Number of subjects: 0
Study 7804020 — intervention group
Group type: EXPERIMENTAL
Intervention: All three substance types (sin conception)
Number of subjects: 0
Study 3132668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin with doxycycline
Number of subjects: 62
Study 3132668 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin with amikacin
Number of subjects: 62
Study 31333258 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-learning sessions incorporated into the pharmacology course
Number of subjects: 0
Study 28376966 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of a multimedia disk regarding injury victims
Number of subjects: 1584
Study 28376966 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of safety brochures
Number of subjects: 1584
Study 28376966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing to parents from schools discussing the risk of fireworks and limiting the fireworks budget
Number of subjects: 1584
Study 28376966 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-to-peer education by trained students about the risks of fireworks
Number of subjects: 1584
Study 28376966 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1584
Study 25966132 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiochemotherapy
Number of subjects: 40
Study 25966132 — intervention group
Group type: COMPARATOR
Intervention: Traditional radiotherapy
Number of subjects: 40
Study 23386053 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine infusion at 4 mL/h for 64 hours
Number of subjects: 200
Study 23386053 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 200
Study 23386053 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine infusion
Number of subjects: 200
Study 21574787 — intervention group
Group type: EXPERIMENTAL
Intervention: Q500 (500 mg quercetin·day(‐1))
Number of subjects: 941
Study 21574787 — intervention group
Group type: EXPERIMENTAL
Intervention: Q1000 (1000 mg quercetin·day(‐1))
Number of subjects: 941
Study 21574787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study 21574787 — intervention group
Group type: EXPERIMENTAL
Intervention: Q500 and Q1000
Number of subjects: 941
Study 17272998 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg intravenously
Number of subjects: 28
Study 17272998 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg intravenously as infusion
Number of subjects: 28
Study 17272998 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg intravenously as bolus injection
Number of subjects: 28
Study 15585685 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a daily dose of 33 microg/kg (0.1 U/kg)
Number of subjects: 77
Study 15585685 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for >2 years before puberty
Number of subjects: 77
Study 15585685 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for <2 years before puberty
Number of subjects: 77
Study 15585685 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 77
Study 12522981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 0
Study 9629064 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid lumbosacral orthosis (SRLSO)
Number of subjects: 15
Study 9629064 — intervention group
Group type: COMPARATOR
Intervention: No belt
Number of subjects: 15
Study 7887378 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography with pacing (TEEP)
Number of subjects: 55
Study 7887378 — intervention group
Group type: COMPARATOR
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 55
Study 2237720 — intervention group
Group type: EXPERIMENTAL
Intervention: EEA circular stapler
Number of subjects: 250
Study 2237720 — intervention group
Group type: COMPARATOR
Intervention: Single layer sutured anastomoses
Number of subjects: 250
Study 842813 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.1-0.2 mg i.v.
Number of subjects: 74
Study 842813 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg i.m. (if required)
Number of subjects: 74
Study 29698924 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomics and transcriptomics investigation in a controlled human malaria infection trial
Number of subjects: 0
Study 29698924 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomics data
Number of subjects: 0
Study 29698924 — intervention group
Group type: EXPERIMENTAL
Intervention: Top pathways during infection
Number of subjects: 0
Study 29698924 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-immune group
Number of subjects: 0
Study 29698924 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of transcriptomics and metabolomics
Number of subjects: 0
Study 29698924 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional experiment
Number of subjects: 0
Study 26802979 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101
Study 26802979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 24604835 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient intravenous cefepime 50 mg/kg (12 hourly)
Number of subjects: 81
Study 24604835 — intervention group
Group type: COMPARATOR
Intervention: Inpatient intravenous cefepime 50 mg/kg (12 hourly)
Number of subjects: 81
Study 22411278 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Melodic Intonation Therapy (MMIT)
Number of subjects: 30
Study 22411278 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 30
Study 21055277 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 68
Study 21055277 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 68
Study 18203246 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM)
Number of subjects: 286
Study 18203246 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent Decision Making
Number of subjects: 286
Study 18203246 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor Decision Making
Number of subjects: 286
Study 18203246 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and Age Influence
Number of subjects: 286